New Research on Drug-Resistant TB Treatment Presented at ATS 2019
Two of TB Alliance’s academic collaborators presented findings from scientific research related to drug-resistant forms of tuberculosis at the American Thoracic
Press Releases
TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
Joint Statement on Universal Health Coverage and TB Research
Joint Statement for Multi-stakeholder Hearing on UHC: Product Development Partnerships “We face a collective challenge in ensuring that everyone—regardless where
A Conversation with Karl Hofmann
We spoke with Karl Hofmann, president and CEO of Population Services International (PSI), to hear about his time serving as
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan
Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis
March 20, 2019 – Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis, released today, outlines what is needed
TB Medicine Pretomanid Enters Regulatory Review Process in the United States
NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has
Compound Studied in TB to be Evaluated in the Treatment of Leishmaniasis
NEW YORK (February 5, 2019) – TB Alliance applauds the Wellcome Trust’s commitment of over £10 million to the Drugs
Played Red Dead Redemption 2? Here’s what you should know about TB
Please note: this article discusses a major plot point of Red Dead Redemption 2 For players of Red Dead Redemption
Jan Lundberg Joins TB Alliance Board of Directors
NEW YORK (January 15, 2019)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has